The Immune Tolerance Network (ITN) is currently seeking short “Concept Proposals” for novel combination therapy clinical trials designed to induce immune tolerance in allergy and asthma. The ITN is especially interested in the following:
- Studies with a tolerance endpoint that combine allergen-specific approaches with other immunomodulatory agents
- The development of novel tolerance assays to investigate allergen-specific mechanisms of clinical tolerance
The ideal proposal would have strong preclinical data, some safety and efficacy experience, and a fully described, testable mechanism of tolerance induction. The ITN is particularly interested in proposals for Phase II trials. See additional details here.
Proposals should be submitted by August 17th, 2012 for a decision in October, 2012.
ITN representatives will be present at the upcoming American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting in Orlando, FL (March 2-6, 2012), if you would like to set up a time to discuss this RFP or potential clinical trial ideas.
Please direct all proposal submissions and any questions concerning this RFP to Philip Bernstein, PhD: pbernstein@immunetolerance.org.